AC Immune SA
NASDAQ:ACIU

Watchlist Manager
AC Immune SA Logo
AC Immune SA
NASDAQ:ACIU
Watchlist
Price: 2.8 USD -2.78% Market Closed
Market Cap: 277m USD

AC Immune SA
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

AC Immune SA
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
AC Immune SA
NASDAQ:ACIU
Revenue
CHf4.4m
CAGR 3-Years
4%
CAGR 5-Years
-22%
CAGR 10-Years
-24%
ADC Therapeutics SA
NYSE:ADCT
Revenue
$75.2m
CAGR 3-Years
-22%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Revenue
$38.3m
CAGR 3-Years
40%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Revenue
CHf236.2m
CAGR 3-Years
16%
CAGR 5-Years
11%
CAGR 10-Years
18%
Idorsia Ltd
SIX:IDIA
Revenue
CHf232.5m
CAGR 3-Years
69%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Kuros Biosciences AG
SIX:KURN
Revenue
CHf118.4m
CAGR 3-Years
98%
CAGR 5-Years
109%
CAGR 10-Years
N/A
No Stocks Found

AC Immune SA
Glance View

Market Cap
281.1m USD
Industry
Biotechnology

AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 143 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

ACIU Intrinsic Value
15.62 USD
Undervaluation 82%
Intrinsic Value
Price

See Also

What is AC Immune SA's Revenue?
Revenue
4.4m CHF

Based on the financial report for Sep 30, 2025, AC Immune SA's Revenue amounts to 4.4m CHF.

What is AC Immune SA's Revenue growth rate?
Revenue CAGR 10Y
-24%

Over the last year, the Revenue growth was -89%. The average annual Revenue growth rates for AC Immune SA have been 4% over the past three years , -22% over the past five years , and -24% over the past ten years .

Back to Top